Table 1 Characteristics of the 25 patients enrolled in the canakinumab trial

From: The IL-1β inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trial

Characteristic

 

Age, y, median (range)

74 (58–88)

Male, n (%)

15 (60)

Hemoglobin, g/dL, median (range)

8.2 (6.6–9.5)

WBC × 109/L, median (range)

3.2 (2.2–5.9)

ANC × 109/L, median (range)

1.7 (0.38–3.96)

Platelets × 109/L, median (range)

129 (16–430.0)

Bone marrow blast %, median (range)

2 (1–4)

WHO 2022 diagnosis, n (%)

 

 MDS-LB

12 (48)

 MDS-SF3B1

11 (44)

 MDS-5q

1 (4)

 MDS-f

1 (4)

IPSS, n (%)

 

 Low

4 (16)

 Intermediate-1

21 (84)

IPSS-R, n (%)

 

 Low

12 (48)

 Intermediate

12 (48)

 High

1 (4)

IPSS-M, n (%)

 

 Low

5 (20)

 Moderate low

6 (24)

 Moderate high

7 (28)

 High

5 (20)

 Very high

2 (8)

Number of mutations per patient, median (range)

3 (1–10)

Number of pre-treatment PRBC unitsa, median (range)

3 (0–16)

Transfusion dependency, n (%)

24 (96)

Prior HMA treatment, n (%)

20 (80)

Number of prior lines of therapy, median (range)

2 (1–5)

  1. Data are median (range), n (%), or n/N (%).
  2. WBC white blood cells, ANC absolute neutrophil counts, WHO World Health Organization, MDS-LB MDS with low blasts, MDS-5q MDS with low blasts and isolated 5q deletion, MDS-SF3B1 MDS with low blasts and SF3B1 mutation, MDS-f MDS with fibrosis, Complex ≥ 3 alterations, Mutations ≥ 5% percentage, HMA hypomethylating agent, PRBC packed red blood cell, IPSS International Prognostic Scoring System, IPSS-R Revised International Prognostic Scoring System, IPSS-M Molecular International Prognostic Scoring System.
  3. aBaseline transfusion status was defined during the 8-week period prior to canakinumab initiation.
Back to article page